Hepatocytes are the most abundant cells of the liver and are involved in many critical functions of the body, including the majority of metabolism of endogenous and exogenous substances. Though cells lines derived from the liver, like HepG2 and HepaRG, are available, they lack the full complement of enzymes and transporters at physiologically relevant expression levels. Hepatocytes in vitro retain most of their in vivo function, especially phase I and phase II metabolism and transport activities and at physiologically relevant levels. Due to these attributes, hepatocytes are recognized as the gold standard for determining drug metabolism and safety profiling by researchers, pharmaceutical industry and regulatory agencies.
Hepatocytes may be used from fresh isolations or from cryopreserved preparations. Hepatocytes are utilized in suspension cultures for studies lasting for less than six hours such as metabolic stability, inhibition of metabolic enzymes or uptake transporter assays. Therefore, cryopreserved human hepatocytes in suspension provide an ideal reagent to study human-specific metabolic profiling and DDI.
Below is a link to a webinar that is being presented by Drug Discovery and Development, in association with our collaborative partner, Celsis IVT. Celsis provides a variety of products that can be used for in-vitro ADME/Tox applications, such as human and animal microsomes and hepatocytes. A portion of the validation data for their LiverPool™ Human Liver Hepatocytes will be taken from a project that was recently completed between BioTek, Celsis IVT, and Promega Corporation. The project highlighted the ability to automate cell-based Cytochrome P450 (CYP) inhibition assays in 384-well format. A set of known CYP inhibitors was profiled against CYP1A2, -2C9, and -3A4. The assays were run using hepatocytes, as well as human liver microsomes, also from Celsis IVT. While only a portion of the data will be shared during the webinar, a more comprehensive summary of the project will be posted at BioTek.com. We invite you to attend the webinar to learn more about the project, and the cells used to generate the data.
By, BioTek Instruments, Brad Larson, Principal Scientist